SBFMW · Sunshine Biopharma, Inc.

Sunshine Biopharma demonstrated continued top-line growth in fiscal 2025, with revenue increasing 4.1% to $36.3 million, driven by the expansion of its generic prescription drug portfolio. Gross profit improved to $12.26 million from $10.67 million in the prior year. However, the company's bottom line was impacted by rising operating costs, specifically within General & Administrative (G&A) expenses, which rose to $18.48 million. Management attributed the increase in G&A expenses primarily to a non-cash, non-recurring impairment charge of $1.75 million related to intangible assets. Excluding this charge, management indicated that operating performance reflected meaningful improvement over 2024. Consequently, the net loss widened to $5.98 million compared to $5.13 million in the prior year. Operationally, the company launched nine new generic drugs and raised $2.46 million in gross proceeds through a registered direct offering to support sales expansion. Looking forward, Sunshine Biopharma implemented cost-reduction initiatives in January 2026 targeting a reduction in G&A expenses by approximately $2 million to $3 million, aiming to sharpen focus on achieving near-term profitability. The company also continues to advance its proprietary pipeline, including the K1.1 mRNA therapeutic candidate and PLpro protease inhibitor antiviral candidate.